Format

Send to

Choose Destination
Ann Oncol. 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11.

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Author information

1
Breast Cancer Translational Research Laboratory/Breast International Group, Institut Jules Bordet, Brussels Department of Pathology and TCRU, GZA, Antwerp, Belgium.
2
Institute of Pathology, Charité -University Hospital, Berlin, Germany.
3
Perlmutter Cancer Center, New York University Medical School, New York, USA.
4
Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
5
European Institute of Oncology (IEO) and University of Milan, Milan, Italy.
6
Department of Pathology GZA, TCRU Hospitals and CORE Antwerp University, Antwerp, Belgium.
7
Genomic Health, Inc., Redwood City, USA University of California San Francisco, San Francisco, USA.
8
Clermont-Ferrand Biopathology, University of Auvergne, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France.
9
Division of Haematology/Medical Oncology and.
10
Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Jacksonville.
11
Department of Pathology, The UT M.D. Anderson Cancer Center, Boston.
12
Department of Pathology, Brigham and Women's Hospital, Boston Department of Cancer Biology, Dana Farber Cancer Institute, Boston.
13
Department of Cancer Biology, Dana Farber Cancer Institute, Boston Department of Cancer Biology, Harvard Medical School, Boston, USA.
14
Istituto Europeo di Oncologia, Milan, Italy.
15
Genomic Health, Inc., Redwood City, USA.
16
Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels.
17
Department of Pathology, University Hospital Leuven, Leuven, Belgium.
18
Department of Medicine, Department of Obstetrics and Gynecology and Women's Health, Albert Einstein Medical Center, Bronx, USA.
19
Laboratory Medicine Program, University Health Network, University of Toronto, Toronto.
20
Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, Canada.
21
Department of Pathology, Yale University School of Medicine, New Haven.
22
Department of Pathology, Stanford University Medical Centre, Stanford.
23
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, USA.
24
German Breast Group, Neu-Isenburg, Germany.
25
Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy.
26
Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, USA.
27
Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
28
Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia sherene.loi@petermac.org.

Abstract

BACKGROUND:

The morphological evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer (BC) is gaining momentum as evidence strengthens for the clinical relevance of this immunological biomarker. Accumulating evidence suggests that the extent of lymphocytic infiltration in tumor tissue can be assessed as a major parameter by evaluation of hematoxylin and eosin (H&E)-stained tumor sections. TILs have been shown to provide prognostic and potentially predictive value, particularly in triple-negative and human epidermal growth factor receptor 2-overexpressing BC.

DESIGN:

A standardized methodology for evaluating TILs is now needed as a prerequisite for integrating this parameter in standard histopathological practice, in a research setting as well as in clinical trials. This article reviews current data on the clinical validity and utility of TILs in BC in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections, acknowledging the future potential of molecular/multiplexed approaches.

CONCLUSIONS:

The methodology provided is sufficiently detailed to offer a uniformly applied, pragmatic starting point and improve consistency and reproducibility in the measurement of TILs for future studies.

KEYWORDS:

breast cancer (BC); clinical validity; prediction; prognosis; tumor-infiltrating lymphocytes (TILs)

PMID:
25214542
PMCID:
PMC6267863
DOI:
10.1093/annonc/mdu450
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center